ReviewCurrent rheumatology reports2004
Antibodies in scleroderma: direct pathogenicity and phenotypic associations.
Review in Current rheumatology reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 57 citations in OpenAlex.
- Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.The Journal of rheumatology · 2017Trial
- Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis.Science translational medicine · 2024Review
- A comparative study of different antiviral treatment protocols in HCV related cryoglobulinemic vasculitis.Scientific reports · 2024Article
- Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.Annals of the rheumatic diseases · 2023Article
- Extracellular matrix stiffness-The central cue for skin fibrosis.Frontiers in molecular biosciences · 2023Review
- Heart disease in the course of systemic sclerosis - an observational study.Reumatologia · 2022Article
- Serum IgG Profiling of Toddlers Reveals a Subgroup with Elevated Seropositive Antibodies to Viruses Correlating with Increased Vaccine and Autoantigen Responses.Journal of clinical immunology · 2021Article
- Management of systemic sclerosis: the first five years.Current opinion in rheumatology · 2020Review
- Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.International journal of molecular sciences · 2020Review
- Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.Arthritis research & therapy · 2019Article
- Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Scleroderma and dentistry: Two case reports.Journal of medical case reports · 2016Article
- Topoisomerase I in Human Disease Pathogenesis and Treatments.Genomics, proteomics & bioinformatics · 2016Review
- Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis.Arthritis research & therapy · 2016Article
- A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations.BMC bioinformatics · 2015Article
- Prevalence and predictive factors of osteoporosis in systemic sclerosis patients: a case-control study.Oncotarget · 2015Article
- Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III.Arthritis care & research · 2015Article
- Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.Molecular & cellular proteomics : MCP · 2012Article
- Toll-like receptor driven B cell activation in the induction of systemic autoimmunity.Seminars in immunology · 2011Review
- Primary biliary cirrhosis: what do autoantibodies tell us?World journal of gastroenterology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Scleroderma is an autoimmune disease involving endothelial cell damage and fibroblast overproduction of extracellular matrix. Several autoantibodies present in the sera of patients with scleroderma, including anti-endothelial cell, antifibroblast, anti-matrix metalloproteinase, and antifibrillin-1 antibodies, may directly contribute to disease pathogenesis. Scleroderma also is characterized by the presence of antinuclear and antinucleolar antibodies, which correlate with particular phenotypes. These include antitopoisomerase-I, anticentromere, antihistone, anti-polymyositis/scleroderma, anti-Th/To, anti-U3-small nucleolar ribonucleoprotein particle, anti-U1-small nuclear ribonucleoprotein particle, anti-RNA polymerase, and anti-B23 antibodies. Other antibodies classically associated with other autoimmune diseases, such as antiphospholipid, antineutrophil cytoplasmic, and antimitochondrial antibodies, also have been described in patients with scleroderma. This review will summarize the various autoantibodies associated with scleroderma, their putative pathogenic roles, and their phenotypic correlations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.